Business Wire

BURLINGTON, Ontario--(BUSINESS WIRE)--$ANRG #ANRG--Anaergia Inc. (“Anaergia” or the “Company”) (TSX: ANRG) will release its fourth quarter and 2022 year-end financial results on Monday, March 27, 2023, before market open. Conference Call and Webcast Details A conference call to review the Company’s...

Strong Engagement and Working Group Workshop Validates Strategic Imperatives and New Business Use Cases WAKEFIELD, Mass.--(BUSINESS WIRE)--The Innovative Optical and Wireless Network Global Forum (IOWN Global Forum), which seeks to create a smarter, more connected world, released a new version...

– Data from pivotal SUNFISH study showed increases in motor function observed during the first year were maintained through the fourth year, while the overall rate of adverse events continued to decrease – – Data confirm long-term efficacy and safety...

- Contributing to higher performance semiconductors - TOKYO--(BUSINESS WIRE)--Dai Nippon Printing Co., Ltd. (DNP, TOKYO: 7912) has developed a Glass Core Substrate (GCS) targeting next-generation semiconductor packages. The new product replaces conventional resin substrates (ex. FC-BGA: Flip Chip-Ball Grid Array)...

MELBOURNE, Australia--(BUSINESS WIRE)--Rio Tinto today published an independent report based on a global audit of its Cultural Heritage Management compliance and performance – one of a number of steps it is taking to continue to find better ways to...

Results presented at AAD 2023 demonstrated that investigational agent LEO 138559 met its primary endpoint of change in the Eczema Area and Severity Index (EASI) compared with placebo1 Efficacy analysis showed significant improvement versus placebo across a variety of endpoints...

Late-Breaking Abstract and Oral Presentation at American Academy of Dermatology Annual Meeting Stage 1 of ongoing 52-week China pivotal AD trial met primary and secondary endpoints No efficacy plateau at Week 16 SAN DIEGO & TAICANG, China & SUZHOU, China--(BUSINESS WIRE)--Connect Biopharma...

Extensive updates from broad and innovative portfolio also to be presented The 2023 American Academy of Dermatology (AAD) Annual Meeting will see the data premiere of the phase III OLYMPIA 2 trial, where nemolizumab monotherapy met all primary and...

I&T Career Expo 2023 offers 2,500+ jobs from over 250 companies to attract global talent HONG KONG--(BUSINESS WIRE)--Hong Kong Science and Technology Parks Corporation (HKSTP) is taking its “Talent Game On 2K23” talent programme to another level with its finale...

Results for TAK-279 (Formerly NDI-034858) Show a Significantly Greater Proportion of Patients Achieved Psoriasis Area and Severity Index (PASI) 75 at Doses ≥5mg at 12 Weeks1 At the Highest Dose of TAK-279, 46% of Patients Achieved PASI 90 and 33%...